AGP Picks
View all

US Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.

Press releases published on October 29, 2026

Acute Ocular Pain Market Expected to Grow Steadily at an 8.3% CAGR Until 2030
The Acute Hospital Care Market Is Projected to Grow at a Steady 6.6% CAGR Driven by Expanding Industry Applications
The Acute Myocardial Infarction Market Is Projected to Grow at a 5.7% CAGR by 2030
The Acute Ischemic Stroke Diagnosis Market is projected to grow to $3.5 billion by 2030, CAGR of 7.2%.
Acute Myeloid Leukemia Market Outlook Report Including Segment Analysis and Key Industry Insights
The Acute Coronary Syndrome Market is projected to grow to 0.12 billion by 2030, expanding at a CAGR of 12.
Acute On Chronic Liver Failure (ACLF) Market Report Analyzes Market Trends, Segment Details, and Business Approaches
Recent Acute Pancreatitis Market Analysis by The Business Research Company Highlights Upcoming Industry Trends
Strom Strategies Calls for a Possible "Black Box Warning" on Al Sayed’s Medicare for All Proposal
BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
Stryker reports third quarter 2026 operating results
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
Merit Medical Reports Third Quarter 2026 Results: Delivers 9% Organic Constant Currency Revenue Growth and Raises Full-Year 2026 Guidance
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Supernus Announces Third Quarter 2026 Financial Results
Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

US Healthcare Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.